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Abstract
Background: Current strategies for gene therapy of inherited diseases consist in adding functional
copies of the gene that is defective. An attractive alternative to these approaches would be to
correct the endogenous mutated gene in the affected individual. This study presents a quantitative
comparison of the repair efficiency using different forms of donor nucleic acids, including synthetic
DNA oligonucleotides, double stranded DNA fragments with sizes ranging from 200 to 2200 bp
and sequences carried by a recombinant adeno-associated virus (rAAV-1). Evaluation of each gene
repair strategy was carried out using two different reporter systems, a mutated eGFP gene or a
dual construct with a functional eGFP and an inactive luciferase gene, in several different cell
systems. Gene targeting events were scored either following transient co-transfection of reporter
plasmids and donor DNAs, or in a system where a reporter construct was stably integrated into
the chromosome.
Results: In both episomal and chromosomal assays, DNA fragments were more efficient at gene
repair than oligonucleotides or rAAV-1. Furthermore, the gene targeting frequency could be
significantly increased by using DNA repair stimulating drugs such as doxorubicin and phleomycin.
Conclusion: Our results show that it is possible to obtain repair frequencies of 1% of the
transfected cell population under optimized transfection protocols when cells were pretreated
with phleomycin using rAAV-1 and dsDNA fragments.
Background
The conventional approach for treatment of genetic disor-
ders by gene therapy is gene addition that consists of sup-
plying a functional cDNA copy of the defective gene. This
can be achieved by delivering the desired DNA sequences
to the target cells using either viral or non viral methods.
An alternative to this strategy is to correct the endogenous
mutated gene in the affected individual through gene
repair. In principal, genetic repair strategies have signifi-
cant therapeutic and safety advantages over the traditional
cDNA gene therapy approaches when treating inherited
diseases [1]. A targeting approach would extend the possi-
bility of therapeutic correction to both recessive and dom-
inant diseases [2]. The corrected gene would be under the
control of its cognate control sequences, ensuring cell-spe-
cific and appropriate level and duration of expression [3].
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Gene targeting is expected to be stable and would mini-
mize limitations due to the size of the gene to be corrected
as well as the risk linked to insertional mutagenesis. Last,
short DNA fragments or synthetic oligonucleotides are
often sufficient as donor sequences and are likely to be
more efficiently routed into the nucleus than large plas-
mid DNA constructs used in gene replacement
approaches [4].
Several gene repair strategies were developed over the last
two decades, including the use of single- [5,6] and double-
stranded DNA fragments [7-11], small single-stranded oli-
gonucleotides [12-14], RNA-DNA chimeras [15-17] and
triple-helix forming oligonucleotides [18,19]. As it is the
case for plasmid DNA, these nucleic acid-based repair ele-
ments can be introduced by non viral delivery methods.
Another repair approach that has been described consists
of using recombinant adeno-associated virus (rAAV)
[20,21] or lentiviral vectors [22]. Most of these strategies
displayed low but detectable activity in cell lines. In other
studies, gene modification was reported in primary and
transformed cells [9,23], in hematopoietic progenitor
cells [24,25] or in animal models such as the CFTR mouse
and dystrophic mice and dogs [16,26-28]. Although high
correction frequencies have been reported, in particular
by using RNA/DNA chimeraplasts [29,30], they remain
the subject of controversy [31-34]. Most often, targeted
alteration of genomic DNA in mammalian cells occurs at
frequencies that are only detectable by highly sensitive
assays.
A current problem has been a difficulty in comparing the
repair frequencies obtained by different methods, because
the experimental conditions are rarely identical (e.g., dif-
ferences in the target gene, the cell line, the transfection
method). By taking this into consideration, the studies
presented here compare gene correction efficiency of
modified and non-modified single-stranded oligodeoxy-
nucleotides (ssODN) to linear double-stranded DNA
(dsDNA) fragments and a recombinant AAV-1 vector
using both episomal and chromosomal targets. Further,
we have assessed whether pre-treatment of target cells
with drugs that stimulate DNA repair, such as doxorubicin
and phleomycin, can increase gene correction. The data
indicate that dsDNA fragments or rAAV-1 result in chro-
mosomal repair frequencies of ~1% when the cells are
pretreated with phleomycin.
Results
Generation and characterization of the mutated reporter 
constructs
Since gene repair frequencies are often difficult to assess
either because of their frequency or because there is not a
selectable assay system, highly sensitive assays are a major
requirement. Although sensitive, PCR-based assays can
lead to artefacts if the experiments are incorrectly per-
formed [35-37]. In contrast, reporter genes provide a con-
venient means to evaluate gene targeting efficacy. The
luciferase  gene encodes a protein that produces light
through an enzymatic reaction and is particularly attrac-
tive because it is sensitive and can be easily quantified.
Repairing a mutated gene instead of inducing a mutation
is preferable because it is easier to measure an increase in
function above background than to detect a small
decrease in a high level of activity [38]. The peGFPLucMut
plasmid (Figure 1A) has a premature stop codon gener-
ated by a single nucleotide change in the open reading
frame, upstream of the luciferase enzyme catalytic site. To
confirm that the mutation introduced inactivates luci-
ferase activity and does not affect the fluorescence proper-
ties of eGFP, the peGFPLucMut plasmid was compared to
the wild-type expression cassette peGFPLuc (Figure 1C).
Therefore, HEK293T cells were transfected with both plas-
mids and were analysed 40 h post-transfection for luci-
ferase and GFP activity. A > 2 × 104-fold reduction in
luciferase activity was observed with the mutant construct
as compared to the wild-type plasmid (Figure 1C). Flow
cytometric analysis showed that inactivation of the luci-
ferase gene only resulted in a 2- to 3-fold decrease of both
the number of eGFP positive cells (Figure 1C) and in the
mean fluorescence (not shown). This minor effect of the
luciferase mutation on the activity of the upstream eGFP
coding sequences could be due to mRNA destabilization
caused by the premature stop codon, through the Non-
sense-Mediated Decay pathway [39].
A second target vector was developed to estimate the per-
centage of cells in which repair occurred. To this end, a
point mutation that causes a premature stop codon was
introduced into the eGFP open reading frame of the
peGFP-C1 plasmid, creating the pmeGFP plasmid (Figure
1B) and abolishing GFP fluorescence [40] (Figure 1C).
Episomal gene correction with single-stranded 
oligodeoxynucleotides
Episomal gene repair assays were performed with ssODNs
designed to target the point mutations introduced into the
two reporter genes. Preliminary studies were conducted to
determine the optimal transfection conditions and target/
ssODN ratio to achieve efficient gene repair. In HEK293T
cells, Lipofectamine mixed with 1.75 μg/well of target
peGFPLucMut plasmid and amounts of ssODN corre-
sponding to a molar ratio (target plasmid/ssODN) of 1/
100 gave the highest gene correction efficiency (Figure
2A). Using these conditions, the transfection efficiency
measured with the peGFPLucMut construct reproducibly
ranged between 18 and 25%.
We then compared the ability of modified and non-mod-
ified ssODNs to repair the point mutation carried by the
luciferase gene of the peGFPLucMut plasmid. Notably, all
antisense repair Luc ssODNs harbor the same nucleotidicBMC Biotechnology 2009, 9:35 http://www.biomedcentral.com/1472-6750/9/35
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Reporter constructs and correction agents Figure 1
Reporter constructs and correction agents. (A) Representation of the peGFPLucMut plasmid. A premature stop codon 
(black plain bar) was introduced into the luciferase portion of the eGFP-Luciferase fusion gene driven by a CMV promoter. (B) 
In the pmeGFP plasmid, the eGFP gene harbors a premature stop codon (black plain bar) and a silent mutation (white bar) used 
as tag sequence. The following information are given for the repair target vectors: the asterisk indicates the position of the 
mutation to correct and the half-arrows represent the location of the primers used to produce the dsDNA fragments. The 
length of homology between the gene repair agents and the targeted sequences are represented below each vector. Sequence 
of the primers used to generate the dsDNA fragments were as follows: F2200, 5'-AAATGTCGTAACAACTCCGCC-3'; 
F1000, 5'-TACAACTACAACAGCCACAAC-3'; F500, 5'-CGCCAAAAACATAAAGAAAGG-3'; F200, 5'-GCTATGAAGAGA-
TACGCCCT-3'; R2200, 5'-AATGTAGCCATCCATCCTTGTC-3'; R1000, 5'-AATCTCACGCAGGCAGTTC-3'; R500, 5'-
CGAACGTGTACATCGACTG-3'; R200, 5'-CAACACCGGCATAAAGAATTG-3' and R700, 5'-TGCTCAGGTAGTGGTT-
GTCG-3. CMV, immediate-early cytomegalovirus promoter (white box); eGFP gene (light grey box); Luciferase gene (dark 
grey box); pA, SV40 early mRNA polyadenylation box. BglII and XbaI, location of the BglII and XbaI restriction sites. (C) Luci-
ferase activity and transfection efficiency expressed as a percentage obtained with HEK293T cells using different plasmids.
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Episomal ssODN-mediated gene repair assay Figure 2
Episomal ssODN-mediated gene repair assay. (A) Dose-curve for molar ratios of plasmid/Luc PO AS 45-mer. Total pro-
tein content (black diamonds) is shown on the right y-axis. (B) HEK293T cells were transfected with both, Luc targeting oligo-
nucleotides and the repair target vector peGFPLucMut using the molar ratio plasmid/gene repair agent of 1/100. Two days 
after, cell samples were submitted to luciferase activity measurement to quantify the gene repair efficiency (left y-axis). Total 
protein content is indicated with the black squares. (C) Similar experiments as in (B) were conducted with the eGFP targeted 
oligonucleotides and the mutated pmeGFP using the molar ratio plasmid/gene repair agent of 1/100. The repair was followed 
by eGFP positive cells counting using flow cytometry. Luc, luciferase; GFP, green fluorescent protein; AS, antisense; S, sense; 
PO, phosphodiester; PS, phosphorothioate; LNA, locked nucleic acid; 35, 35mer; 45, 45mer; Ctr, non-correcting control oligo-
nucleotide; Rep, repair oligonucleotide.
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Table 1: List of the single-stranded oligodeoxynucleotides used to target the mutated genes
Name Size Sequence Characteristics
Luc PO AS Ctr 35 b 5'-TGATTTGTATTCAGCCCCTATCGTTTCATAGCTTC-3' Antisense Control phosphodiester ssODN
Luc PO S Ctr 35 b 5'-GAAGCTATGAAACGATAGGGGCTGAATACAAATCA-3' Sense Control phosphodiester ssODN
Luc PS AS Ctr 35 b 5'-TsGsAsTTTGTATTCAGCCCCTATCGTTTCATAGCsTsTsC-3' Antisense Control ssODN with 3 PS linkages at each end
Luc PS S Ctr 35 b 5'-GsAsAsGCTATGAAACGATAGGGGCTGAATACAAAsTsCsA-3' Sense Control ssODN with 3 PS linkages at each end
Luc PS AS Ctr 45 b 5'-TsTsCsTGTGATTTGTATTCAGCCCCTATCGTTTCATAGCTTCTGsCsCsA-3' Antisense Control ssODN with 3 PS linkages at each end
Luc PO AS Rep 35 b 5'-TGATTTGTATTCAGCCCATATCGTTTCATAGCTTC-3' Antisense phosphodiester ssODN
Luc PO S Rep 35 b 5'-GAAGCTATGAAACGATATGGGCTGAATACAAATCA-3' Sense phosphodiester ssODN
Luc PS AS Rep 35 b 5'-TsGsAsTTTGTATTCAGCCCATATCGTTTCATAGCsTsTsC-3' Antisense ssODN with 3 PS linkages at each end
Luc PS S Rep 35 b 5'-GsAsAsGCTATGAAACGATATGGGCTGAATACAAAsTsCsA-3' Sense ssODN with 3 PS linkages at each end
Luc PO AS Rep 45 b 5'-TTCTGTGATTTGTATTCAGCCCATATCGTTTCATAGCTTCTGCCA-3' Antisense phosphodiester ssODN
Luc PS AS Rep 45 b 5'-TsTsCsTGTGATTTGTATTCAGCCCATATCGTTTCATAGCTTCTGsCsCsA-3' Antisense ssODN with 3 PS linkages at each end
Luc PO S Rep 45 b 5'-TsGsGsCAGAAGCTATGAAACGATATGGGCTGAATACAAATCACAsGsAsA-3' Sense ssODN with 3 PS linkages at each end
Luc LNA 1.1 AS Rep 45 b 5'-TTCTGTGATTTGTATTCAGCCCATATCGTTTCATAGCTTCTGCCA-3' Antisense ssODN with 1 LNA residue at each end
Luc LNA 4.4 AS Rep 45 b 5'-TTCTGTGATTTGTATTCAGCCCATATCGTTTCATAGCTTCTGCCA-3' Antisense ssODN with 4 LNA residues at each end
Luc LNA 4r AS Rep 45 b 5'-TTCTGTGATTTGTATTCAGCCCATATCGTTTCATAGCTTCTGCCA-3' Antisense ssODN with 4 LNA residues distributed over the 
sequence
GFP PO AS Ctr 35 b 5'-TGGTCACGAGGGTTGGCTAGGGCACGGGCAGCTTG-3' Antisense Control phosphodiester ssODN
GFP PS AS Ctr 35 b 5'-TsGsGsTCACGAGGGTTGGCTAGGGCACGGGCAGCsTsTsG-3' Antisense Control ssODN with 3 PS linkages at each end
GFP PO AS Rep 35 b 5'-TGGTCACGAGGGTTGGCCAGGGCACGGGCAGCTTG-3' Antisense phosphodiester ssODN
GFP PS AS Rep 35 b 5'-TsGsGsTCACGAGGGTTGGCCAGGGCACGGGCAGCsTsTsG-3' Antisense ssODN with 3 PS linkages at each end
Luc, luciferase; GFP, green fluorescent protein; AS, antisense; S, sense; Ctr, non-correcting control oligonucleotide; Rep, repair oligonucleotide; PO, phosphodiester; PS, phosphorothioate; LNA, 
locked nucleic acid (underlined); s, phosphorothioate linkage; in bold, position of the base to correct.BMC Biotechnology 2009, 9:35 http://www.biomedcentral.com/1472-6750/9/35
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sequence and were designed to hybridize the mutated
eGFPLuc in such a way that the correcting base is posi-
tioned in the center of the nucleotide chain of 35 and 45
residues (Table 1). When transfected, the 35-mer PO-AS
control oligonucleotide (Luc PO-AS Ctr) generated luci-
ferase activity levels that were similar to those obtained
with the peGFPLucMut plasmid alone. This indicates that
the control ODN does not induce repair of the point
mutation, as expected. By contrast, co-transfection of the
mutated plasmid with the repair 35-mer PO-AS oligonu-
cleotide (Luc PO-AS Rep) resulted in reporter gene activity
that were 5-times higher than control levels (Figure 2B).
Despite the advantageous sensitivity of the luciferase sys-
tem, it is still difficult to determine the percentage of cells
which have undergone gene correction. To address this
question, we used the pmeGFP plasmid as target for the
episomal gene correction assays employing oligonucle-
otides (Table 1) designed to target the premature stop
codon. By using the same experimental conditions as with
the peGFPLucMut targeting, control and antisense repair
oligonucleotides (35 nucleotides) were compared. Nota-
bly, the ODN sequence used was previously found to be
the most efficient for repair of pmeGFP [40]. As shown in
Figure 2C, the correcting ODNs generated ~2% GFP posi-
tive cells while the control ODNs did not lead to detecta-
ble levels of GFP expression. These results clearly indicate
that the tools and experimental conditions we developed
allowed us to detect DNA repair events.
Furthermore, oligonucleotides containing different modi-
fications were designed and evaluated (Table 1). The
study compared the gene correction potential of antisense
35- and 45-mer ssODNs harboring (Luc PS-AS Rep) or not
(Luc PO-AS Rep) three phosphorothioate linkages at each
end. These modifications were included to protect the oli-
gonucleotides from exonuclease degradation. The results
show that the repair efficiency is not significantly higher
with the PS-modified ODNs (Figure 2B). This was also the
case when comparing the PS ODN designed to repair the
pmGFP to the PO ODN (Figure 2C). Transfection of the
35- and 45-mer antisense ODNs generated higher luci-
ferase activities than their sense counterparts, indicating a
strand bias in repair of episomal gene targets [14]. It is
also interesting to note that the addition of 10 nucleotides
to the ODNs results in an insignificant modification of
the repair capacity (comparison between 35- and 45-mer
ODNs).
Locked nucleic acids (LNAs) residues within the repair
fragment were also examined in terms of their ability to
improve the efficiency of repair. These residues have a
methylene bridge connecting the 2'-oxygen with the 4'-
carbon of ribose. The rationale for including such residues
lies in the fact that LNAs were shown to display a higher
affinity to DNA residues than DNA itself, and therefore
may stabilize the ODN/DNA interactions and result in a
higher frequency of repair [41,42]. The effect of including
LNA residues was studied with 3 ODNs: two had the LNA
residues at each end (4 and 1 residues at each end for LNA
4.4 and LNA 1.1, respectively). The third contains four
LNAs residues distributed over the whole sequence (Table
1). Notably, the Tm measurements showed that LNA 4.4
and LNA 4r, increased the Tm by 3–4°C; whereas the Tm
remained unchanged as compared to the PO oligonucle-
otides when there was 1 LNA residue introduced at each
end of the ODN. In vitro results show that, although the 3
antisense oligonucleotides mediate gene repair, none was
more efficient than the PS or PO ODNs (Figure 2C and
data not shown). It is also worth noting that there is no
difference between oligonucleotides harboring one or
four LNA residues at the extremities. In addition, the pres-
ence of an LNA residue near the target base unfavorably
affects the correction efficiency as was indicated with the
Luc LNA 4r AS ODN (data not shown).
Episomal gene correction with double-stranded DNA 
fragments
To evaluate the impact of DNA fragment size on the repair
efficiency, dsDNA fragments with sizes ranging from 200
to 2200 bp were generated. As for the ssODNs, the frag-
ments were generated such that they were able to anneal
with the eGFPLuc ORF (Table 2) and that the target base
was placed in the center of the fragment. This latter point
is important since previous studies have indicated that the
frequency of homologous recombination is dependent on
the length of homologous sequence flanking each side of
the mutated site [43]. Care was also taken to ensure that
the DNA fragments did not overlap flanking regulatory
sequences such as the promoter region (Figure 1A). This is
necessary to eliminate the possibility that the resulting
luciferase expression was not due to spurious activation of
the gene. For each size, the repair (Rep) and control (Ctr)
fragments were compared for their repair efficiency. Using
the same transfection conditions as with ssODNs, the tar-
get/dsDNA fragment ratio resulting in the highest gene
correction efficiency was 1/10 (Figure 3A). As with the
ssODNs, the plasmid transfection efficiency ranged
between 18 and 25%. The episomal repair assays with the
different DNA fragments gave the following results: 1)
transfection using the repair DNA fragments resulted in
luciferase expression levels that were at least two orders of
magnitude higher than those obtained with the control
fragments (Figure 3B), 2) the frequency of repair increases
slightly with the size of the repairing DNA fragment
(Rep), with a plateau size of 500 bp, and 3) the data
shows that dsDNA-mediated repair is about ten-fold more
efficient than ssODNs (comparing the results of Figure 2A
and 3A, generated in the same experiment).
To quantify the percentage of cells repaired, a 700 bp
dsDNA fragment was generated using the wild-type and
the mutant eGFP genes as templates, respectively (TableBMC Biotechnology 2009, 9:35 http://www.biomedcentral.com/1472-6750/9/35
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2). Figure 3C shows that about 7% of the entire cell pop-
ulation was eGFP positive after repair. When compared to
the ssODN PO-AS, the results indicated that the dsDNA
fragment was significantly more efficient in repairing the
point mutation than the ssODN (Figure 2C and 3C).
Episomal gene correction with rAAV-1
Adeno-associated virus (AAV) is a single-stranded, linear
DNA virus with a 4.7 kb genome consisting of the viral rep
and cap genes flanked by inverted terminal repeat (ITR)
sequences. AAV vectors containing foreign DNA between
the ITRs (Figure 1) can be packaged by rep and cap gene
products supplied in trans. By using this methodology, a
rAAV-GFPLuc vector pseudotyped with serotype 1 capsid
proteins (rAAV1) was generated and then used in the epi-
somal gene correction assays. It contains a 2.4 kb eGFPLuc
fragment that is only a little larger than the 2.2 kb frag-
ment used in the dsDNA-mediated repair assays. The frag-
ment is flanked by the two inverted terminal repeats of
AAV serotype 2 (Figure 1). Use of this recombinant AAV
vector allows direct comparison of the repair efficiency
between transfected dsDNA and the rAAV-1 vector. Pre-
liminary studies were conducted to determine the optimal
transfection and infection conditions for efficient gene
repair. In HEK293T cells, transfection of 1.75 μg of peGF-
PLucMut followed by rAAV infection gave the highest effi-
ciency (data not shown). By using these optimized
conditions and multiplicities of infection (MOI) from 1
000 to 300 000, the ability of rAAV-GFPLuc vectors to
restore luciferase activity to the mutant reporter construct
was evaluated. Infection of non-transfected cells with the
rAAV-GFPLuc vectors resulted in luciferase levels similar
to those obtained with cells transfected with the target
plasmids alone. However, addition of rAAV-GFPLuc to
transfected cells showed a significant increase of the luci-
ferase activity (Figure 4A). At MOIs = of 3000, the luci-
ferase levels were comparable to those observed with
dsDNA fragments (Figure 3B and 4). Although not fully
homologous to the gene to repair due to the presence of
about 1650 nt of the luciferase gene, correction of
pmeGFP transfected HEK293T cells by rAAV GFPLuc
resulted in 1.38% GFP positive cells (Figure 4B). Notably,
a similar efficiency was obtained with the rAAV-GFP vec-
tor (Figure 1B), indicating that the luciferase segment of
the rAAV-GFPLuc did not negatively interfere with the
repair process (data not shown).
Table 2: List of the double-stranded DNA fragments used to target the mutated genes
Name Size Sequence
200 dsDNA Ctr 195 bp 5'-CGGCA..//..TGGCAGAAGCTATGAAACGATAGGGGCTGAATACAAATCACAGAA..//..TGTTG-3'
3'-GCCGT..//..ACCGTCTTCGATACTTTGCTATCCCCGACTTATGTTTAGTGTCTT..//..CAAGC-5'
500 dsDNA Ctr 494 bp 5'-CACGT..//..TGGCAGAAGCTATGAAACGATAGGGGCTGAATACAAATCACAGAA..//..GTTCG-3'
3'-GTGCA..//..ACCGTCTTCGATACTTTGCTATCCCCGACTTATGTTTAGTGTCTT..//..CAAGC-5'
1000 dsDNA Ctr 980 bp 5'-TACAA..//..TGGCAGAAGCTATGAAACGATAGGGGCTGAATACAAATCACAGAA..//..AGATT-3'
3'-ATGTT..//..ACCGTCTTCGATACTTTGCTATCCCCGACTTATGTTTAGTGTCTT..//..TCTAA-5'
2200 dsDNA Ctr 2133 bp 5'-AAATG..//..TGGCAGAAGCTATGAAACGATAGGGGCTGAATACAAATCACAGAA..//..ACATT-3'
3'-TTTAC..//..ACCGTCTTCGATACTTTGCTATCCCCGACTTATGTTTAGTGTCTT..//..TGTAA-5'
200 dsDNA Rep 195 bp 5'-CGGCA..//..TGGCAGAAGCTATGAAACGATATGGGCTGAATACAAATCACAGAA..//..TGTTG-3'
3'-GCCGT..//..ACCGTCTTCGATACTTTGCTATACCCGACTTATGTTTAGTGTCTT..//..CAAGC-5'
500 dsDNA Rep 494 bp 5'-CACGT..//..TGGCAGAAGCTATGAAACGATATGGGCTGAATACAAATCACAGAA..//..GTTCG-3'
3'-GTGCA..//..ACCGTCTTCGATACTTTGCTATACCCGACTTATGTTTAGTGTCTT..//..CAAGC-5'
1000 dsDNA Rep 980 bp 5'-TACAA..//..TGGCAGAAGCTATGAAACGATATGGGCTGAATACAAATCACAGAA..//..AGATT-3'
3'-ATGTT..//..ACCGTCTTCGATACTTTGCTATACCCGACTTATGTTTAGTGTCTT..//..TCTAA-5'
2200 dsDNA Rep 2133 bp 5'-AAATG..//..TGGCAGAAGCTATGAAACGATATGGGCTGAATACAAATCACAGAA..//..ACATT-3'
3'-TTTAC..//..ACCGTCTTCGATACTTTGCTATACCCGACTTATGTTTAGTGTCTT..//..TGTAA-5'
GFP 700 dsDNA Ctr 732 bp 5'-AAATG..//..CAAGCTGCCCGTGCCCTAGCCAACCCTCGTGACCA..//..GAGCA-3'
3'-TTTAC..//..GTTCGACGGGCACGGGATCGGTTGGGAGCACTGGT..//..CTCGT-5'
GFP 700 dsDNA Rep 732 bp 5'-AAATG..//..CAAGCTGCCCGTGCCCTGGCCAACCCTCGTGACCA..//..GAGCA-3'
3'-TTTAC..//..GTTCGACGGGCACGGGACCGGTTGGGAGCACTGGT..//..CTCGT-5'
Ctr, non-correcting control fragment; Rep, repair fragment; GFP, green fluorescent protein; in bold, position of the base to correct.BMC Biotechnology 2009, 9:35 http://www.biomedcentral.com/1472-6750/9/35
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Episomal dsDNA-mediated gene repair Figure 3
Episomal dsDNA-mediated gene repair. (A) Dose-curve for molar ratios of plasmid/1000 ds DNA Rep. Total protein 
content (black diamonds) is shown on the right y-axis (B) HEK293T cells were transfected with Luc dsDNA fragments and the 
target vector peGFPLucMut using the molar ratio plasmid/gene repair agent of 1/10 (plain bars). Two days after, cell samples 
were submitted to luciferase activity measurement to quantify the gene repair efficiency (left y-axis). Total protein content 
(black squares) is shown on the right y-axis. (C) Similar experiments than in (B) were conducted with the GFP targeted dsDNA 
fragment and the pmeGFP vector using the molar ratio plasmid/gene repair agent of 1/10 (plain bars). The repair efficiency was 
measured by eGFP positive cells counting using flow cytometry. For each dsDNA fragments: Ctr, non-correcting control frag-
ment; Rep, repair dsDNA fragment.
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Drug-enhanced DNA repair
Previous reports have shown that DNA damaging agents
can increase the efficiency of gene repair [44,45]. In the
present study, 3 drugs that activate DNA repair pathways
were evaluated for their ability to augment the three dif-
ferent gene repair systems. Initial studies were carried out
with the anthracyclin antibiotic doxorubicin (Dox), a
commonly used anti-neoplastic agent that has been
shown to inhibit the activity of topoisomerase II which
results in the generation of single and double-strand DNA
breaks. This, in turn, stimulates DNA repair mechanisms.
HEK293T cells were preincubated with doxorubicin at
concentrations ranging from 0.1 to 300 nM. The cells were
transfected with the pmeGFP plasmid and the GFP PO AS
Rep oligonucleotide (Table 1). Figure 5A shows that Dox
improves the gene correction frequency mediated by
ssODN in a dose-dependent manner with an optimum at
30 nM resulting in a 3-fold increase of the proportion of
repaired cells. No eGFP positive cells were detected when
the non-correcting control oligonucleotide was used (data
not shown). Treated and non-treated cells were compared
after transfection with the pmeGFP reporter plasmid
mixed either with the GFP dsDNA 700 control or correct-
ing fragment, or the rAAV repair vector. No statistically
significant increase of the gene correction rate in the pres-
ence of Dox was observed with either repair system (Fig-
ure 5A).
The other compounds that were tested for their ability to
stimulate DNA repair were troxerutin and phleomycin
D1. The former compound is a derivative of the natural
flavonoid rutin which has been shown to enhance the
repair of radiation-induced DNA strand breaks [46], while
the latter one is a glycopeptide antibiotic of the bleomycin
family that is able to cleave DNA [47]. As with Dox, the
cells were incubated with increasing amounts of drug and
were then co-transfected with the mutated plasmid and
the repair agents. While troxerutin did not improve the
repair frequencies (data not shown), phleomycin D1
(PLM) increased the repair efficiency of pmeGFP by about
2 to 3-fold with all three gene repair systems (Figure 5B).
Since the treatment of cells with doxorubicin was reported
to alter the cell cycle [48], the cells were assayed for the
effect of the experimental conditions on cell cycle. While
non-treated cells exhibited a normal cell cycle profile with
standard population distributions in the G1, S and G2
phases (Figure 5C), cells treated with 30 nM Dox showed
a shift of the population towards the G2 phase (Figure
5C). Cells treated for 24 h with 33 μM of PLM also showed
a strong population shift towards the late S/early G2
phase as compared to non-treated cells (Figure 5C).
Chromosomal gene repair
Episomal gene correction assays are useful for evaluating
gene targeting systems because they are not time-consum-
ing and they tend to generate higher gene repair frequencies
when compared to chromosomal targeting. This is proba-
bly due to the high number of targets (plasmids) present
during the episomal correction procedure. A better mimic
of the therapeutic situation would be to evaluate targeting
at the chromosomal level. Therefore, a clone of CHO cells
carrying a genomic pmeGFP (CHO-meGFP-12) was gener-
ated. The initial repair experiments were conducted with
Episomal rAAV-mediated gene repair Figure 4
Episomal rAAV-mediated gene repair. (A) HEK293T cells were infected with an increasing multiplicity of infection (MOI) 
of the rAAV2/1-GFPLuc vector following (dark grey bars) or not (white bars) a transfection step with the target vector peGF-
PLucMut. Two days after, cell samples were submitted to luciferase activity measurement to quantify the gene repair efficiency 
(left y-axis). Total protein content is shown on the right y-axis (squares for repair conditions and triangles for the control 
experiments). (B) Similar experiment as in (A) conducted with the target vector pmeGFP followed by eGFP positive cells 
counting to determine the repair frequency.
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Lipofectamine as the transfection reagent in the episomal
assays. However, under these conditions and even with a
transfection efficiency ranging between 30 and 40%, no
repair events were detected. In contrast, with nucleofection,
gene correction frequencies of 2 × 10-5 and 2 × 10-4 were
observed with the PO AS Rep oligos and the GFP 700
dsDNA Rep fragments, respectively. No corrected cells were
detected when using the control oligonucleotide or the
control dsDNA fragment (GFP PO AS Ctr and GFP 700
dsDNA Ctr). Using the rAAV-1-GFPLuc vector, a repair fre-
quency of about 1 × 10-4 was observed (Figure 6A). It
should be noted that the efficiency of nucleofection and
AAV-mediated transduction of CHO cells are similar (i.e. 7
versus 11% of GFP positive cells), and is the basis for mak-
ing a comparison between both gene repair systems.
Assessment of correction stability and transmission to
daughter cells following exposure to ssODN-, dsDNA-
and rAAV was achieved by propagating the cells under
selective conditions. Analysis at day 5 and 21 for the pro-
portion of eGFP-positive cells indicated that there is no
decline of the proportion of eGFP-positive cells when
comparing the proportion at day 5 to day 21 (ssODN: 1.4
× 10-5 and 2 × 10-5, dsDNA: 8.1 × 10-5 and 8.4 × 10-5, rAAV:
1.2 × 10-4 and 2.19 × 10-4 eGFP-positive cells at day 5 and
21, respectively).
To avoid issues arising from growth and/or survival
among the repaired cells clonal expansion was evaluated.
Single-cell sorting of the eGFP-positive cells (i.e. repaired
cells) was performed at day 5. For each condition, 288
cells were isolated and checked as to their ability to form
a colony. About 85% (85%, 83%, 84% and 82% for
mock-treated, ssODN-, dsDNA-, and rAAV-treated cells,
respectively) of cells not only survived but were able to
form colonies. Among the repaired cells and in the pres-
ence of neomycin (selection pressure) ~60% displayed
GFP fluorescence whereas most of the ~40% non-fluores-
cent cells became eGFP positive after incubation with 100
nM of trichostatin A (a histone deacetylase inhibitor used
to abrogate the silencing of the CMV promoter). Thus,
indicating that the apparent loss of expression can be
attributed to transgene silencing.
Next, doxorubicin or phleomycin were assessed for their
potential to promote gene correction at the chromosomal
level. Using the optimized conditions of pre-incubation
of the cell cultures with the stimulatory agents previously
defined, chromosomal gene correction assays were per-
formed using the CHO-meGFP-12 clone. The results indi-
cate that 30 nM of doxorubicin increases the gene
correction frequency by 3-fold both for the oligonucle-
otides and the DNA fragments, while the AAV-repair was
not significantly increased. Phleomycin (33 μM)
increased the correction frequency of both, ssODN and
dsDNA 700 bp by 5-fold, and the efficiency of rAAV-1 by
10-fold (Figure 6B). Under these conditions, up to 0.1%
of repair events occur with the two latter drugs in the over-
all cell population. It has been previously shown that
aminoglycosides can force stop codon readthrough [49].
To exclude the possibility that GFP expression after phle-
omycin treatment was due to stop codon readthrough,
CHO-meGFP-12 cells were nucleofected with a control
oligonucleotide in the presence of phleomycin. 5 days
Doxorubicin and phleomycin stimulation of ssODN-, dsDNA-,  and rAAV-mediated episomal gene repair Figure 5
Doxorubicin and phleomycin stimulation of ssODN-, 
dsDNA-, and rAAV-mediated episomal gene repair. (A) 
HEK293T cells were treated with increasing doses of doxoru-
bicin 24 h prior to transfection with the pmeGFP plasmid and 
either the GFP PO AS Rep oligonucleotide (molar ratio 1/100, 
grey bars), the GFP dsDNA 700 fragment (molar ratio 1/10, 
white bars) or with the rAAV-GFPLuc vector (black bars). (B) 
HEK293T cells were exposed to various doses of phleomycin 
24 h prior to transfection with the pmeGFP plasmid and either 
the GFP PO AS Rep oligonucleotide (molar ratio 1/100, grey 
bars), the GFP dsDNA 700 fragment (molar ratio 1/10, white 
bars) or with the rAAV-GFPLuc vector (black bars). (C) Cell 
cycle distribution of non-treated (left), doxorubicin-treated 
(middle) and phleomycin-treated cells (right).
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after transfection, no GFP expression was detected, indi-
cating that the GFP fluorescence obtained with the repair
oligonucleotides was due to gene correction and not to
stop codon readthrough.
Discussion
The aim of the present study was to evaluate the gene edit-
ing efficiency of: i- double-stranded DNA fragments of
various sizes, ii- different synthetic single-stranded DNA
oligonucleotides and iii- a rAAV2/1 vector. To efficiently
detect the repair events, two mutated reporter plasmids
were generated. The peGFPLucMut expression vector
allows for a highly sensitive evaluation of the repair
events, while giving the possibility to report the rescued
luciferase activity to a percentage of transfected cells. On
the other hand, measurement of gene editing at the single
cell level, employed assays for targeted modification of a
mutated GFP.
The activity of the different repair systems was first evalu-
ated in episomal targets. Experiments where the repair
agent was co-transfected with the target gene were useful
because the repair frequency was generally 10 to 100-fold
higher than gene targeting at the chromosomal level [50].
These assays check whether the oligonucleotides or DNA
fragments are able to repair a given mutation and com-
pare repair efficiencies in various cell lines. These experi-
ments also enabled the optimization of transfection
conditions as well as provided information about the
optimal dose of the repairing DNA. The data in the
HEK293T cells was consistent with findings by other
groups using other reporter systems, cell lines and/or
transfection methods. Among these, we observed that the
repair frequency increases with the size of the DNA frag-
ment [7] and that the antisense Luc PS-AS oligonucleotide
is more efficient than its sense counterpart in repairing an
episomal target [14,50,51]. In addition to testing oligonu-
cleotides with and without 3 phosphorothioate linkages
at each end, studies were undertaken to determine
whether incorporation of locked nucleic acids (LNAs)
into the oligonucleotide sequence can improve the repair
frequency. The rationale for including LNA residues was
based on their greater affinity to DNA residues than that
of DNA itself [42,52]. Thus, it was speculated that LNAs
may stabilize the ODN/DNA interactions and result in a
more efficient repair. However, none of the three LNA
modified ODNs resulted in a higher gene targeting effi-
ciency than the PO or PS oligonucleotide (Figure 2). It is
also interesting to note that dsDNA fragments mediated
higher repair rates than the oligonucleotides and is in
good agreement with results reported by Nickerson and
Colledge [50]. Finally, while the rAAV-1 vector gave luci-
ferase values that were comparable to those obtained with
dsDNA fragments, the number of repair events in the GFP
assay was similar to that observed with oligonucleotides.
Chromosomal repair efficiency was assessed in CHO cells
stably expressing the mutated GFP construct. When Lipo-
fectamine was used as the delivery system, no GFP posi-
tive cells were detected regardless of the repair system
used. Alternatively, nucleofection gave a repair efficiency
of up to 0.02% of the overall cell population. Taking into
consideration a transfection efficiency of ~10% the actual
repair frequency was 0.2% of the transfected cells. This
efficiency is comparable to that observed previously by
Radecke and co-workers [40] who observed between 0.1
and 0.5% HEK293 cells repaired.
Comparing the different repair systems, roughly the same
hierarchy was observed in the episomal and the chromo-
somal repair experiments. These results are in disagree-
ment with the data published by Nickerson and Colledge
[50] who found that dsDNA fragments were more effi-
cient than oligonucleotides in mediating gene repair in
the episomal assays while they obtained opposite results
in the chromosomal targeting studies. The authors suggest
that this difference may be due to the fact that the ODNs
have an increased mobility in the cytoplasm due to their
small size and thus enter the nucleus more efficiently.
While this is likely, it does not account for the episomal
targeting where the dsDNA fragments were more efficient.
Another possible explanation for the differences observed
Chromosomal gene repair assay Figure 6
Chromosomal gene repair assay. CHO-meGFP-12 cells, 
pre-incubated (B) or not (A) with doxorubicin (30 nM) or phle-
omycin (33 μM) were nucleofected with 7.5 μg of GFP PO AS 
ssODNs or GFP 700 dsDNA fragments or infected with the 
rAAV-GFPLuc vector (MOI = 300000).
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between the chromosomal targeting in the previous study
[50] and the present study is that nucleofection and not
lipofection was used as delivery method. Of course, other
transfection agents, including cationic polymers may lead
to similar results than Nucleofection. Taken together, our
results suggest that, when delivered with a comparable
efficiency, dsDNA fragments more efficiently repair chro-
mosomal genes than ODNs.
The fact that the AAV-1 vector showed correction frequen-
cies that are lower than those of dsDNA fragments was
unexpected given the previously reported chromosomal
gene targeting rates for AAV of up to 1% [53,54]. Since
AAV-mediated repair frequencies of 0.1% or below have
also been reported [55-57] it is possible that there were
multiple parameters, such as the target gene, the cell type
and the nature of the mutation that influence the efficacy
of repair. To the best of our knowledge, previous compar-
isons between AAV and non-viral repair systems were
made indirectly by comparing repair frequencies reported
in the literature. Due to the lack of standardized assay con-
ditions, large variations in the rate of gene repair are not
surprising and make indirect comparisons somewhat
dubious. Furthermore, a recent study showed that homol-
ogous recombination is required for AAV-mediated gene
targeting [58]. This could explain the similarities in repair
efficiency and behaviour observed between AAV and lin-
ear DNA fragments in the presence of doxorubicin or
phleomycin. However, this does not preclude that there
are mechanistic differences between the two repair sys-
tems. Moreover, it has been previously shown that linear
single- and double-stranded DNA fragments show similar
correction efficiencies [5]. This is consistent with episo-
mal repair results using dsDNA and sense and antisense
single-stranded DNA fragments of 1000 and 2200 bases
generated by asymmetric PCR (data not shown).
In summary, our episomal and chromosomal gene correc-
tion studies suggest that, in the absence of drugs such as
phleomycin, AAV vectors are less efficient for gene target-
ing than linear dsDNA fragments. Nevertheless, AAVs
remain interesting repair systems due to their ability to
transduce a large variety of cells, including primary cells.
The efficient nuclear delivery of DNA, even in non-divid-
ing cells, and the recent development of different AAV
serotypes that display different patterns of transduction in
a diverse array of tissues may be particularly relevant to
the use of AAV vectors as gene editing agents. On the other
hand, non-viral delivery of dsDNA fragments represents
an easier, and potentially safer, way to initiate gene repair
than AAV.
Finally, the efficiency of chromosomal gene targeting was
significantly increased by treating cells with doxorubicin
or phleomycin. It is still unclear whether the enhanced
repair was due to the capacity of these drugs to stimulate
the DNA repair machinery; however, it is known that
dsDNA as well as AAV- and oligonucleotide-mediated
repair peaks in the S-phase [59,60]. Since both drugs shift
the cell population towards S/G2, the possibility that the
increased repair is, at least, in part caused by this popula-
tion shift in the cell cycle is a probable outcome.
Representative scheme of the rAAV production procedure Figure 7
Representative scheme of the rAAV production procedure. Recombinant AAV vectors were generated using a three-
plasmid transfection protocol. Briefly, HEK293 cells were tri-transfected using polyethylenimine (PEI 25 kDa; Aldrich) with the 
helper plasmid carrying adenovirus helper functions, the packaging plasmid expressing the rep and cap genes and the rAAV vec-
tor plasmid containing the vector genome sequence. Three days after, cells were harvested and lysed to release the recom-
binant vectors from the producer cells. Samples were centrifuged at 1500 g for 15 minutes at 4°C and supernatants were 
treated with 25 U/ml benzonase for 30 minutes at 37°C, centrifuged at 10000 g for 20 minutes at 4°C. Then, one volume of 
cold saturated ammonium sulfate was added to supernatants and samples were incubated 1 h on ice and centrifuged at 12 000 
g for 30 minutes at 4°C to precipitate the recombinant viral particles. rAAVs, resuspended in PBS with Ca2+ and Mg2+ were 
then purified by 2 rounds of ultracentrifugation on isopycnic CsCl2 gradients. The vector-containing fractions were then pooled 
and desalted by dialysis against sterile PBS supplemented with Ca2+ and Mg2+. Purified recombinant vectors were aliquoted and 
stored at -80°C. For the titration of the physical particles, an aliquot was treated with DNAse I for 10 minutes at 37°C to elim-
inate residual DNA. Then, the sample was treated with proteinase K to degrade the capsids and to release the viral DNA. Viral 
genome titer of the sample was then determined by real-time qPCR.
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Conclusion
In conclusion, we would like to emphasize that, despite the
apparent low efficiency of targeted gene correction in some
cell systems, one can not exclude its use as therapeutic option.
In particular when considering ex vivo strategies with stem cells
[24,61,62]. It has also been shown in mice that a single
hematopoietic stem cell is capable of repopulating bone mar-
row [63]. Therefore, clinical application of gene repair may be
feasible when considering treatment for a genetic disease such
as X-linked SCID (SCID-X1) where repair of the mutant γc
gene in only a small number of cells can be therapeutic [64].
Moreover, by associating targeted gene repair with chromo-
somal site-specific double strand breaks, that were shown to
dramatically increase the correction efficiency of oligonucle-
otides [65], AAV [57], dsDNA fragments [66,67] and lentivi-
ral vectors [22] gene correction may become a promising
therapeutic alternative to conventional gene therapy for the
treatment of genetic disorders in the future.
Methods
Materials
Dulbecco's modified Eagle's medium (DMEM) with 4.5 g/
L glucose and sodium pyruvate, phosphate buffered saline
(PBS), Lglutamine, penicillin and streptomycin were pur-
chased from Gibco BRL. Foetal calf serum was purchased
from HyClone. peGFPLuc and peGFP-C1 plasmids were
obtained from Clontech. Lipofectamine Reagent and
Optimem-I medium were purchased from Invitrogen.
Doxorubicin chloride (Sigma) and troxerutin (Sigma)
dilution stocks were prepared extemporaneously in
DMEM and water, respectively. Phleomycin D1 was pur-
chased from Cayla (Invivogen).
Generation of the mutated reporter constructs
The mutated sequences in peGFPLucMut (6367 bp) and
pmeGFP (4731 bp) are shown in Figure 1. The peGFPLuc-
Mut plasmid is a derivative of the peGFPLuc plasmid,
where one point mutation (T963G, Tyr→*) was intro-
duced into the luciferase portion of the open reading
frame (ORF) of the eGFP::Luciferase fusion gene. This
mutation generates a premature stop codon upstream of
the catalytic site of the luciferase enzyme. The point muta-
tion was introduced using the Quick Change Site-directed
Mutagenesis Kit from Stratagene (La Jolla, USA) with the
following primers:
5'-TGGCAGAAGCTATGAAACGATAgGGGCTGAATACAAAT-
CACAGAA-3' and 5'-TTCTGTGATTTGTATTCAGCCCcTATC
GTTTCATAGCTTCTGCCA-3'. To generate the pmeGFP plas-
mid, two point mutations (G173A, Trp→* and C177A,
Pro→Pro) were introduced, using the same mutagenesis kit as
above, into the eGFP-C1 open reading frame of the peGFP-C1
plasmid with the following primers:
5'-CCCGTGCCCTaGCCaACCCTCGTGAC-3' and 5'-GTC
ACGAGGGTtGGCtAGGGCACGGG-3'.
The first mutation introduces a premature stop codon into
the eGFP ORF, whereas the second silent mutation consti-
tutes a tag sequence that distinguishes the corrected (sen-
sitive to MscI restriction endonuclease digestion) from the
non-corrected (not digested) plasmids. Plasmids were
purified using Macherey-Nagel kits, resuspended in water,
aliquoted and stored at -20°C.
Gene correcting agents
Oligodeoxynucleotides
All single-stranded oligodeoxynucleotides were synthe-
sized by Sigma, purified by high-performance liquid chro-
matography, resuspended in water, aliquoted and stored
at -20°C. The sequences of the ssODNs are shown in
Table 1. Determination of the melting temperature (Tm)
used the following procedure: the LNA-modified and the
non-modified oligonucleotides were mixed with a single-
stranded complementary DNA fragment (0.05 nmol of
each) in a final volume of 25 μl of Absolute Blue Sybr
ROX buffer 1× (Thermo Scientific). Samples were first
heated to 98°C for 10 min, slowly cooled to 4°C, and
then heated from 40 to 95°C at a rate of 0.2°C/30 s. Meas-
urements were taken every 30 s. Assays were performed on
a Chromo4 thermal cycler (Biorad) and the Tm was calcu-
lated using the accompanying software (ssODN PO: 75.6
± 0.9°C, PS: 74.9 ± 1.1°C, LNA 1.1 AS: 75.0 ± 1.1 °C, LNA
4.4 AS: 79.7 ± 1.0°C, LNA 4r AS: 78.6 ± 1.0°C).
DNA fragments
The dsDNA fragments (195, 494, 980 and 2133 bp) were
designed to correct the luciferase mutation and a 732 bp
fragment designed to correct the eGFP mutation (see
Table 2). The fragments were generated by PCR amplifica-
tion using DyNAzyme EXT DNA polymerase (New Eng-
land Biolabs) and primer pairs F200/R200, F500/R500,
F1000/R1000, F2200/R2200 and F2200/R700, respec-
tively (see legend of Figure 1). After a first round of PCR
amplification (20 cycles), the fragment of interest was gel-
purified to eliminate the plasmids used as templates. A
second round of PCR amplification was then performed
(25 cycles), and the PCR products were subsequently puri-
fied, resuspended in water, aliquoted and stored at -20°C.
The correcting fragments (dsDNA Rep) were generated
using the peGFPLuc and the peGFP-C1 plasmids as tem-
plates whereas the peGFPLucMut and pmeGFP plasmids
were used as templates to generate the non-correcting
control fragments (dsDNA Ctr).
Production, purification and titration of the rAAV vectors
Pseudotyped AAV-2/1 vectors were generated using the
three-plasmid transfection protocol described by Rivière
et al. [68] with minor modifications. Representative
scheme and details about the production, the purification
and the titration processes of the rAAV vectors are given in
the legend of Figure 7. For our purpose, the productions
were realized with the pXX6 adenovirus helper plasmid,BMC Biotechnology 2009, 9:35 http://www.biomedcentral.com/1472-6750/9/35
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the pLT-RC02 packaging plasmid expressing the rep and
cap genes and the pSMD2-eGFPLuc or the pSMD2-eGFP
plasmid. The latter drive the synthesis of the viral genome
composed of the homologous sequences used to target
the mutated genes flanked by the AAV-2 inverted terminal
repeats (ITR). The pSMD2-eGFPLuc plasmid was gener-
ated from the pSMD2-Luc plasmid [69] into which the
NheI-XbaI 2.4 kb fragment of peGFPLuc (which contains
the eGFPLuc ORF) was subcloned between the two
inverted terminal repeats (ITRs) of the XbaI-XbaI 4 kb
fragment-deleted pSMD2-Luc plasmid (total viral genome
size: 2.8 kb). The pSMD2-eGFP plasmid was generated
from pSMD2-eGFPLuc by excising the BglII-XbaI 1.6 kb
fragment containing the Luc ORF. Note that Hirata and
co-workers [20] have previously shown that with a size of
2845 bases, viral genomes are only present as monomers
in rAAV. Since the viral genome containing the 2.4 kb
peGFPLuc fragment has a size of 2.8 kb, we can assume
that our AAV vectors are single stranded.
Cell culture
All cell lines were cultured at 37°C, 5% CO2, and 100%
humidity in DMEM supplemented with 10% heat-inacti-
vated foetal calf serum, 2 mM L-glutamine, 100 U/ml pen-
icillin and 100 ug/ml streptomycin (standard medium).
Only cells that were mycoplasma free and less than 15
passages were used.
Generation and characterization of the CHO-meGFP-12 
cell clone
CHO-K1 cells were transfected using Lipofectamine rea-
gent mixed with StuI linearized pmeGFP plasmids. The
cells were cultivated for 3 days in standard medium before
the addition of geneticin sulfate (600 μg/ml) to select the
stably transfected cells. Two weeks after transfection,
geneticin-resistant colonies were harvested and cloned
with a cell sorter. Clone CHO-meGFP-12 was selected for
the repair experiments. The copy number of the integrated
eGFP mutated expression cassette has been determined by
qPCR using Taqman probes directed against the CMV pro-
moter and the 3' region of the eGFP gene. The clone CHO-
meGFP-12 contains 20 non-concatemerized copies of the
eGFP mutated expression cassette. The absence of con-
catemers was demonstrated by nested PCR amplifying all
the possible forms of concatenation.
Gene correction assays
Episomal gene correction assays were performed as fol-
lows: plasmid DNA- and the gene repair agent (ssODN
and dsDNA)- complexes were generated separately in
Optimem-I medium with Lipofectamine Reagent using a
cationic lipid/DNA (w/w) ratio of 4:1. Exponentially
growing HEK293T cells were harvested and 105 cells were
seeded into a 24-well plate containing 1 ml of standard
medium supplemented or unsupplemented with DNA
repair stimulating drugs (e.g. doxorubicin, troxerutin or
phleomycin). The next day, culture medium was dis-
carded, cells pre-incubated with the repair activating
drugs, were washed once with standard medium. The
transfection mixture was then added in a final volume of
0.5 ml/well. After a 3 h incubation, the transfection
medium was removed and fresh standard medium was
added until analysis. When rAAV vectors were used as
repair agent, the culture medium was removed one hour
after the transfection step (which allowed for the delivery
of the mutated reporter construct) and replaced by the
infection mixture consisting of diluted rAAV-2/1 vectors
(0.25 ml medium/well). The infection mixture was
removed after 12 h and replaced with fresh medium.
Analyses of the episomal repair frequencies were per-
formed 48 hours after the transfection/infection.
Chromosomal gene correction experiments with ssODN
and DNA fragments involved seeding 2 × 106 cells into a
culture flask in medium that was either supplemented
with drugs or unsupplemented. After an overnight incuba-
tion, the cells were washed twice with PBS, detached with
trypsin-EDTA 0.05% and then resuspended in standard
medium before centrifugation at 200 × g for 10 minutes.
The cell pellet was resuspended in Solution T (from
Amaxa Biosystem) at a concentration of 1.2 × 107 cells per
ml. A 100 μl aliquot of the cell suspension was slowly
mixed with 7.5 μg of the gene correction agent before
nucleofection with program U-23 of the Nucleofector II
device (Amaxa Biosystem). After nucleofection cells were
immediately seeded into 10 cm dishes containing pre-
warmed standard medium and were grown under selec-
tion (600 μg/ml Geneticin) for five days before analysis.
When using rAAV vectors for chromosomal gene correc-
tion, exponentially growing cells were harvested and
seeded into a 24-well plate at a density of 3 × 104/well
without or with drugs. The following day, the cells were
preincubated with DNA repair activating drugs, washed
once with standard medium and then grown in infection
mixture (0.25 ml/well final volume). After a 12 h incuba-
tion, the infection medium was removed, and replaced
with fresh medium and cells were grown in the presence
of 600 μg/ml Geneticin for four days before analysis.
Flow cytometry analysis
Cells were analysed by flow cytometry after they were
detached with trypsin-EDTA 0.05% and diluted in 20 vol-
umes of standard medium. The analysis was carried out
on a Facscalibur flow cytometer (BD; Becton, Dickinson
and Company) using the software CELLQuest, version
3.1f (BD). Quantification of gene repair rates was
achieved using 50 000 morphologically intact cells to
allow detection of eGFP positive cells. The respective
repair rate was calculated as the ratio of morphologically
intact eGFP-positive cells to all morphologically intact
cells. The proportion of eGFP-positive cells is expressed as
a percentage and the values are the means of duplicates.BMC Biotechnology 2009, 9:35 http://www.biomedcentral.com/1472-6750/9/35
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Cell cycle analysis
Cells were harvested with trypsin-EDTA (0.05%), washed
twice with PBS and fixed in 70% cold ethanol. The fixed
cells were then stored for 24 h at 4°C before PI staining
(propidium iodide at 40 μg/ml, DNAse-free RNAseI at 20
μg/ml and 0.1% sodium dodecyl sulfate in PBS) at 37°C
for 3 h. The proportion of cells in each phase of the cell
cycle is expressed as percentage and all values are the
means of duplicates.
Luciferase assay
The luciferase assay was performed as previously
described [70]. Background luciferase activity was sub-
tracted from each value. The protein content of transfected
cells was measured by Bradford dye-binding using the
Biorad protein assay. Luciferase activity levels are
expressed as light units per 10 second per milligram of
protein and the values are the means of duplicates.
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